SciSparc Ltd SPRC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.36
- Day Range
- $5.00–5.27
- 52-Week Range
- $0.47–80.10
- Bid/Ask
- $4.81 / $5.85
- Shares Outstanding
- 565,500.00
- Market Cap
- $2.87M
- Volume/Avg
- 12,270 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 0.02
- Price/Sales
- 0.73
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.scisparc.com
Valuation
|
Metric
|
SPRC
|
|---|---|
Price/Earnings (Normalized) | 0.02 |
Price/Book Value | — |
Price/Sales | 0.73 |
Price/Cash Flow | — |
Price/Earnings
SPRC
Financial Strength
|
Metric
|
SPRC
|
|---|---|
Quick Ratio | 2.33 |
Current Ratio | 2.41 |
Interest Coverage | −1,160.00 |
Quick Ratio
SPRC
Profitability
|
Metric
|
SPRC
|
|---|---|
Return on Assets (Normalized) | 38.70% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 50.55% |
Return on Assets
SPRC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@cxbW%f | LOCK|&j%q | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|KJQKWSk | LOCK|kr<! | $71B | |||
| argenx SE ADR
ARGX
| LOCK|@lRJd@ | LOCK|N$$ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gRfP<FJ | LOCK|R>c | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|K&QWv% | LOCK|DwS&c | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#JBF#W!K | LOCK|$V!% | $26B | |||
| Moderna Inc
MRNA
| LOCK|$dD^n@ | LOCK|K$ | $25B | |||
| Incyte Corp
INCY
| LOCK|Jt#d@> | LOCK|$Qn | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&%c!Wzs | LOCK|$hs | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|tk%j>< | LOCK|<# | $16B |
United States